IL1A and rheumatoid arthritis: IL-1ra is released in vivo during inflammation and immune-mediated diseases [15], which is thought to limit the deleterious effects brought by IL-1 [16], [17] and shown to be effective in the treatment of sepsis, graft-versus-host disease and rheumatoid arthritis in animal models [18], [19], [20], [21].